This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: PCSK9 inhibitors

Introduction

September 2018 Br J Cardiol 2018;25(suppl 2):S3 doi:10.5837/bjc.2018.s06

Introduction

Naveed Sattar

Abstract

The risk of developing type 2 diabetes is amplified among the South Asian population in the UK, with estimates suggesting a two- to fourfold increase in risk. Why is this? Hanif and Susarala review putative reasons why South Asian people represent at least 15% of the population of people with diabetes in this country, and who also carry higher microvascular complication rates than their European counterparts. Although the reasons for excess coronary heart disease (CHD) mortality risk in South Asians are not entirely clear, studies have found higher levels of conventional risk factors present at a younger age, which may be an explanation for

| Full text

November 2017 Br J Cardiol 2017;24:129

NICE publishes updated familial hypercholesterolaemia guidance

BJC Staff

Abstract

While most of the recommendations in the new guideline remain unchanged, there are some key updates including the use of the new lipid modifying drugs- PCSK9 inhibitors (for which NICE technology appraisal guidance exists), treatment of children and recommendations to search medical records for those who may be at risk. The guideline also recommends that those at risk of FH should be offered DNA tests to confirm they have the condition. Previously, low-density lipoprotein cholesterol (LDL-C) levels have been used but they are not always accurate. At the moment only 15% of the estimated 260,000 people in the UK with FH have been diagnosed, inc

| Full text

November 2017 Br J Cardiol 2017;24:136

Cholesterol – a problem solved?

Jaqui Walker

Abstract

Genetic disease The benefits of child-parent screening for familial hypercholesterolaemia (FH), were explored by Professor David Wald (Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London). Detection rates are highest if FH is screened for in children between one to two years of age – a heel prick test, for example, is quick to carry out at routine immunisation appointments and uptake rates of 84% have been achieved. Screening is effective – a rate of four children and four parents are identified for every 1,000 children screened. The child benefits twice: their

| Full text
Innovations in cardiorenal medicine

February 2017 Br J Cardiol 2017;24:13 Online First

Innovations in cardiorenal medicine

Richard Crawley

Abstract

Targeting uric acid Dr Richard Crawley (Portsmouth Hospitals NHS Trust) The conference’s keynote lecture, delivered by Professor Austin Stack (University Hospital, Limerick, Ireland), homed in on the idea that serum uric acid directly contributes to increased cardiovascular disease. This was shown in his team’s work published in 2013,1 which used retrospective data to identify a direct correlation between raised serum uric acid concentrations and increased risk of developing cardiovascular disease. This, therefore, begs two questions: Firstly, does uric acid directly cause vascular endothelial damage, contributing to acute renal dysfunct

| Full text

March 2016 Br J Cardiol 2016;23:9

Confusing NICE guidance on PCSK9 inhibitors

BJCardio Staff

Abstract

Jules Payne hopes NICE will ‘see sense’ about the PCSK9 inhibitors In November 2015, NICE published draft guidance not recommending evolocumab as an option for people with high cholesterol (primary hypercholesterolaemia – heterozygous familial and non-familial) and mixed dylipidaemia. A similar decision for alirocumab followed in February 2016, although only a few days before, the earlier decision for evolocumab had been modified by NICE who said that it could be used for a limited number of NHS patients who are considered to be statin intolerant. HEART UK Chief Executive Ms Jules Payne said: “NICE appear to be confused about

| Full text

October 2015 Br J Cardiol 2015;22:138–142 Online First

News from the European Society of Cardiology Congress 2015

BJCardio Staff

Abstract

(more…)

| Full text

May 2015 Br J Cardiol 2015;22:59–60 Online First

News from the European Atherosclerosis Society Congress

BJCardio Staff

Abstract

FH initiative Headlining the Congress was the launch of the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC), a consortium of major FH registries across Europe, Asia-Pacific, Africa and South America, led by Professor Kausik Ray (Imperial College, London). As shown by the previous EAS Consensus Panel statement, FH is one of the most common inherited conditions, yet it is underdiagnosed and undertreated in almost all countries.1 The FHSC will provide information on key aspects relating to FH care which will be critical in leveraging public policy to improve detection and management. Linking patient and clinician empowerment unde

| Full text

May 2015

European Atherosclerosis Society Congress 2015 Highlights

Professor Naveed Sattar, Professor Børge Nordestgaard, Professor Derick Raal

Abstract

Click to enlarge Three experts give their personal highlights of the 2015 European Atherosclerosis Society Congress in our podcast. Professor Naveed Sattar discusses lifestyle and risk (00:10) Professor Børge Nordestgaard discusses the clinical importance of lipoprotein (a) (05:37) Professor Derick Raal discusses the launch of the Familial Hypercholesterolaemia Studies Collaboration (10:27) More highlights from the Congress are available in our report. This podcast has been made possible due to a grant from Sanofi who have had no control over the content of this podcast. (Job code: SAGB.CMR.15.04.0508; Date of preparation May 2015)

| Full text
New opportunities for cholesterol lowering: focus on PCSK9 inhibitors

July 2014 Br J Cardiol 2014;21:91–3 doi:10.5837/bjc.2014.021

New opportunities for cholesterol lowering: focus on PCSK9 inhibitors

Peter Sever, Judy Mackay

Abstract

(more…)

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now